Tag Archives: NASDAQ:DYN

Lessons Learned on Preparing to Weather the Inevitable Challenges in Biotech
September 15, 2022

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC By all accounts, 2022 did not start according to plan for the biotech industry. The U.S. economy and growth stocks struggled with the

Leave a comment